Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Filippo Pinto e Vairo is active.

Publication


Featured researches published by Filippo Pinto e Vairo.


Genetics and Molecular Biology | 2012

Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis

Taciane Alegra; Filippo Pinto e Vairo; Mônica Vinhas de Souza; Bárbara Côrrea Krug; Ida Vanessa Doederlein Schwartz

The specific treatment available for Fabry disease (FD) is enzyme replacement therapy (ERT) with agalsidase alfa or beta. A systematic review and meta-analysis was conducted to assess the efficacy and safety of ERT for FD. Only double-blind, randomized clinical trials (RCTs) comparing agalsidase alfa or beta and placebo were included. ERT with either agalsidase alfa or beta was considered similar for the purposes of analysis. Ten RCTs were identified, which showed improvements in neuropathic pain, in heart abnormalities and in globotriaosylceramide (GL-3) levels. A meta-analysis showed increased odds for fever, rigors, development of IgG antibodies to agalsidase, and no significant association with development of hypertension or reduction in the QRS complex duration on electrocardiogram. The RCTs included in this comparison enrolled few patients, were highly heterogeneous, and were focused mainly on surrogate endpoints, limiting any conclusions as to the real effect of ERT for FD. The available evidence suggests that response to ERT is variable across patient subgroups and that agalsidase may slow progression of FD, with slight improvement of existing changes. Nevertheless, many uncertainties remain, and further studies are necessary.


Human Mutation | 2013

Analysis of LMNB1 Duplications in Autosomal Dominant Leukodystrophy Provides Insights into Duplication Mechanisms and Allele-Specific Expression

Elisa Giorgio; Harshvardhan Rolyan; Laura E. Kropp; Anish Chakka; Svetlana A. Yatsenko; Eleonora Di Gregorio; Daniela Lacerenza; Giovanna Vaula; Flavia Talarico; Paola Mandich; Camilo Toro; Eleonore Eymard Pierre; Pierre Labauge; Sabina Capellari; Pietro Cortelli; Filippo Pinto e Vairo; Diego Miguel; Danielle Stubbolo; Lourenco Charles Marques; William A. Gahl; Odile Boespflug-Tanguy; Atle Melberg; Sharon Hassin-Baer; Oren S. Cohen; Rastislav Pjontek; Armin Grau; Thomas Klopstock; Brent L. Fogel; Inge Meijer; Guy A. Rouleau

Autosomal dominant leukodystrophy (ADLD) is an adult onset demyelinating disorder that is caused by duplications of the lamin B1 (LMNB1) gene. However, as only a few cases have been analyzed in detail, the mechanisms underlying LMNB1 duplications are unclear. We report the detailed molecular analysis of the largest collection of ADLD families studied, to date. We have identified the minimal duplicated region necessary for the disease, defined all the duplication junctions at the nucleotide level and identified the first inverted LMNB1 duplication. We have demonstrated that the duplications are not recurrent; patients with identical duplications share the same haplotype, likely inherited from a common founder and that the duplications originated from intrachromosomal events. The duplication junction sequences indicated that nonhomologous end joining or replication‐based mechanisms such fork stalling and template switching or microhomology‐mediated break induced repair are likely to be involved. LMNB1 expression was increased in patients’ fibroblasts both at mRNA and protein levels and the three LMNB1 alleles in ADLD patients show equal expression, suggesting that regulatory regions are maintained within the rearranged segment. These results have allowed us to elucidate duplication mechanisms and provide insights into allele‐specific LMNB1 expression levels.


Expert Opinion on Emerging Drugs | 2016

Emerging drugs for the treatment of mucopolysaccharidoses.

Roberto Giugliani; Andressa Federhen; Filippo Pinto e Vairo; Cláudia Vanzella; Gabriela Pasqualim; Letícia Machado Rosa da Silva; Luciana Giugliani; Ana Paula Kurz de Boer; Carolina Fishinger Moura de Souza; Ursula da Silveira Matte; Guilherme Baldo

ABSTRACT Introduction: Despite being reported for the first time almost one century ago, only in the last few decades effective have treatments become available for the mucopolysaccharidoses (MPSs), a group of 11 inherited metabolic diseases that affect lysosomal function. These diseases are progressive, usually severe, and, in a significant number of cases, involve cognitive impairment. Areas covered: This review will not cover established treatments such as bone marrow/hematopoietic stem cell transplantation and classic intravenous enzyme replacement therapy (ERT), whose long-term outcomes have already been published (MPS I, MPS II, and MPS VI), but it instead focuses on emerging therapies for MPSs. That includes intravenous ERT for MPS IVA and VII, intrathecal ERT, ERT with fusion proteins, substrate reduction therapy, gene therapy, and other novel approaches. Expert opinion: The available treatments have resulted in improvements for several disease manifestations, but they still do not represent a cure for these diseases; thus, it is important to develop alternative methods to approach the unmet needs (i.e. bone disease, heart valve disease, corneal opacity, and central nervous system (CNS) involvement). The work in progress with novel approaches makes us confident that in 2017, when MPS will commemorate 100 years of its first report, we will be much closer to an effective cure for these challenging conditions.


Gene | 2013

Genotypic and phenotypic characterization of Brazilian patients with GM1 gangliosidosis

Fernanda Sperb; Filippo Pinto e Vairo; Maira Graeff Burin; Fabiana Quoos Mayer; Ursula da Silveira Matte; Roberto Giugliani

GM1 gangliosidosis is a lysosomal disorder caused by β-galactosidase deficiency due to mutations in the GLB1 gene. It is a rare neurodegenerative disorder with an incidence of about 1:100,000-1:200,000 live births worldwide. Here we review GLB1 mutations and clinical features from 65 Brazilian GM1 gangliosidosis patients. Molecular analysis showed 17 different mutations and c.1622-1627insG was the most frequent, accounting for 50% of the alleles. Cognitive impairment was the main clinical sign, observed in 82% of patients, followed by hepatosplenomegaly observed in 56% of patients. It was possible to establish a significant correlation between age at onset of symptoms preceding the first year of life and the presence of the mutation c.1622-1627insG (p=0.03). Overall our findings differ from literature and represent the exclusive genotypic profile found in Brazilian GM1 gangliosidosis patients.


Clinica Chimica Acta | 2016

Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy

Giovana Brondani Biancini; Carlos Eduardo Jacques; Tatiane Grazieli Hammerschmidt; Heryk Motta de Souza; Bruna Donida; Marion Deon; Filippo Pinto e Vairo; Charles Marques Lourenço; Roberto Giugliani; Carmen Regla Vargas

Fabry disease (FD) is caused by deficient activity of the lysosomal enzyme α-galactosidase A. Its substrates, mainly globotriaosylceramide (Gb3), accumulate and seem to induce other pathophysiological findings of FD. Once enzyme replacement therapy (ERT) is not completely efficient on preventing disease progress in FD patients, elucidating the underlying mechanisms in FD pathophysiology is essential to the development of additional therapeutic strategies. We investigated 58 Fabry patients (23 male and 35 female) subdivided into two groups (at diagnosis and during long-term ERT) and compared them to healthy individuals. Fabry patients at diagnosis presented altered glutathione (GSH) metabolism (higher GSH levels, lower glutathione peroxidase - GPx - and normal glutathione reductase - GR - activities), higher lipid peroxidation levels (thiobarbituric acid reactive species - TBARS - and malondialdehyde - MDA), nitric oxide (NO(.)) equivalents and urinary Gb3. Fabry patients on ERT presented GSH metabolism similar to controls, although lipid peroxidation and urinary levels of NO(.) equivalents remained higher whereas Gb3 levels were lower than at diagnosis but still higher than controls. These data demonstrated that redox impairment occurs in Fabry patients before and after ERT, probably as a consequence of Gb3 accumulation, providing targets to future therapy approaches using antioxidants in combination with ERT in FD.


PLOS ONE | 2016

Phenylketonuria and Gut Microbiota: A Controlled Study Based on Next-Generation Sequencing

Felipe Pinheiro de Oliveira; Roberta Hack Mendes; Priscila Caroline Thiago Dobbler; Volker Mai; Victor Satler Pylro; Sheldon Waugh; Filippo Pinto e Vairo; Lilia Farret Refosco; Luiz Fernando Wurdig Roesch; Ida Vanessa Doederlein Schwartz

Phenylketonuria (PKU) is an inborn error of metabolism associated with high blood levels of phenylalanine (Phe). A Phe-restricted diet supplemented with L-amino acids is the main treatment strategy for this disease; if started early, most neurological abnormalities can be prevented. The healthy human gut contains trillions of commensal bacteria, often referred to as the gut microbiota. The composition of the gut microbiota is known to be modulated by environmental factors, including diet. In this study, we compared the gut microbiota of 8 PKU patients on Phe-restricted dietary treatment with that of 10 healthy individuals. The microbiota were characterized by 16S rRNA sequencing using the Ion Torrent™ platform. The most dominant phyla detected in both groups were Bacteroidetes and Firmicutes. PKU patients showed reduced abundance of the Clostridiaceae, Erysipelotrichaceae, and Lachnospiraceae families, Clostridiales class, Coprococcus, Dorea, Lachnospira, Odoribacter, Ruminococcus and Veillonella genera, and enrichment of Prevotella, Akkermansia, and Peptostreptococcaceae. Microbial function prediction suggested significant differences in starch/glucose and amino acid metabolism between PKU patients and controls. Together, our results suggest the presence of distinct taxonomic groups within the gut microbiome of PKU patients, which may be modulated by their plasma Phe concentration. Whether our findings represent an effect of the disease itself, or a consequence of the modified diet is unclear.


The application of clinical genetics | 2015

Diagnostic and treatment strategies in mucopolysaccharidosis VI

Filippo Pinto e Vairo; Andressa Federhen; Guilherme Baldo; Mariluce Riegel; Maira Graeff Burin; Sandra Leistner-Segal; Roberto Giugliani

Mucopolysaccharidosis VI (MPS VI) is a very rare autosomal recessive disorder caused by mutations in the ARSB gene, which lead to deficient activity of the lysosomal enzyme ASB. This enzyme is important for the breakdown of the glycosaminoglycans (GAGs) dermatan sulfate and chondroitin sulfate, which accumulate in body tissues and organs of MPS VI patients. The storage of GAGs (especially dermatan sulfate) causes bone dysplasia, joint restriction, organomegaly, heart disease, and corneal clouding, among several other problems, and reduced life span. Despite the fact that most cases are severe, there is a spectrum of severity and some cases are so attenuated that diagnosis is made late in life. Although the analysis of urinary GAGs and/or the measurement of enzyme activity in dried blood spots are useful screening methods, the diagnosis is based in the demonstration of the enzyme deficiency in leucocytes or fibroblasts, and/or in the identification of pathogenic mutations in the ARSB gene. Specific treatment with enzyme replacement has been available since 2005. It is safe and effective, bringing measurable benefits and increased survival to patients. As several evidences indicate that early initiation of therapy may lead to a better outcome, newborn screening is being considered for this condition, and it is already in place in selected areas where the incidence of MPS VI is increased. However, as enzyme replacement therapy is not curative, associated therapies should be considered, and research on innovative therapies continues. The management of affected patients by a multidisciplinary team with experience in MPS diseases is highly recommended.


Journal of Neuroimmunology | 2015

Brain-derived neurotrophic factor expression increases after enzyme replacement therapy in Gaucher disease

Filippo Pinto e Vairo; Fernanda Sperb-Ludwig; Matheus Wilke; Kristiane Michellin-Tirelli; Cristina Brinckmann Oliveira Netto; Eurico Camargo Neto; Ida Vanessa Doederlein Schwartz

Mutations in the GBA gene are related to an increased risk of developing neurodegenerative diseases. The exact molecular mechanisms involved in the interaction between GBA and α-synuclein, a protein that has been associated with several neurological diseases, remain unsolved. Brain-derived neurotrophic factor (BDNF) is a neurotrophin that is important for the normal development of the peripheral and central nervous system, and it plays a key role in neuronal survival and synaptic plasticity in the adult brain. A reduction in BDNF expression has been reported in patients with Parkinsons disease, Alzheimers disease and dementia with Lewy bodies. We analyzed BDNF levels in the plasma of Gaucher Disease (GD) patients who were not being treated with enzyme replacement therapy (ERT) and then subsequently following ERT; we compared the levels to those of healthy controls. We demonstrated that BDNF levels were remarkably diminished in GD patients who were under no specific treatment and these levels increased following ERT. This is the first study that demonstrates a variation in the plasma levels of a neurotrophic factor in GD type 1 patients. Further studies are required to correlate BDNF level variations with the clinical findings and the response to therapy in GD patients. Low levels of BDNF are associated with neurodegenerative diseases; therefore, BDNF could provide a new therapeutic target for GD patients with neurological symptoms.


The application of clinical genetics | 2017

Maple syrup urine disease: mechanisms and management

Patrick R. Blackburn; Jennifer Gass; Filippo Pinto e Vairo; Kristen M Farnham; Herjot K. Atwal; Sarah Macklin; Eric W. Klee; Paldeep S. Atwal

Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma, α-ketoacids in urine, and production of the pathognomonic disease marker, alloisoleucine. The disorder varies in severity and the clinical spectrum is quite broad with five recognized clinical variants that have no known association with genotype. The classic presentation occurs in the neonatal period with developmental delay, failure to thrive, feeding difficulties, and maple syrup odor in the cerumen and urine, and can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated. Treatment consists of dietary restriction of BCAAs and close metabolic monitoring. Clinical outcomes are generally good in patients where treatment is initiated early. Newborn screening for MSUD is now commonplace in the United States and is included on the Recommended Uniform Screening Panel (RUSP). We review this disorder including its presentation, screening and clinical diagnosis, treatment, and other relevant aspects pertaining to the care of patients.


Annals of Hematology | 2015

Osteopontin: a potential biomarker of Gaucher disease

Filippo Pinto e Vairo; Fernanda Sperb-Ludwig; Matheus Wilke; Kristiane Michellin-Tirelli; Cristina Brinckmann Oliveira Netto; Eurico Camargo Neto; Ida V.D. Schwartz

Gaucher disease (GD) is one of the most prevalent lysosomal storage disorders and the disorder that has the greatest immune system involvement. Pathologic lipid accumulation in macrophages accounts for a small amount of the additional tissue mass in the liver and spleen. The additional increase may be related to an inflammatory response because Gaucher cells secrete inflammatory mediators. Osteopontin (OPN) is a protein identified in cancer cells and in bone cells that is produced by several types of immune cells including T-cells and macrophages. We report here elevated OPN levels in the plasma of type 1 GD patients and its sensitive response to enzyme replacement therapy. The mean OPN value of GD patients receiving ERT was similar to the values of controls and patients with other lysosomal disorders. When comparing untreated and treated GD patients, the p value was <0.001. In GD, OPN appears to be more sensitive to ERT than chitotriosidase and can be used during the follow-up of patients who are chitotriosidase deficient. Additional extended studies are required to relate variations in the OPN levels to clinical findings and response to therapy in GD patients.

Collaboration


Dive into the Filippo Pinto e Vairo's collaboration.

Top Co-Authors

Avatar

Ida Vanessa Doederlein Schwartz

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Cristina Brinckmann Oliveira Netto

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ida V.D. Schwartz

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Alícia Dorneles Dornelles

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Livia Paskulin

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Divair Doneda

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Marina Siebert

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge